Related Experiment Videos
Oral clodronate therapy for hypercalcemia related to extensive subcutaneous fat necrosis in a newborn
Shuo-Hsun Hung1, Wen-Yu Tsai, Po-Nien Tsao
1Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Insights
This study shows oral clodronate effectively treated severe hypercalcemia in a newborn with subcutaneous fat necrosis when standard therapies failed. This bisphosphonate offers a new treatment option for this rare condition.
Area of Science:
- Neonatal Medicine
- Pediatric Endocrinology
- Pharmacology
Background:
- Subcutaneous fat necrosis in newborns can lead to life-threatening hypercalcemia.
- Bisphosphonates are emerging as a treatment for this condition.
Observation:
- A female infant presented with extensive subcutaneous fat necrosis and intractable hypercalcemia.
- Standard hypercalcemia treatments (hydration, diet, furosemide, glucocorticoids) were ineffective.
Findings:
- Elevated 1,25-dihydroxyvitamin D and suppressed parathyroid hormone confirmed the hypercalcemia mechanism.
- Oral clodronate disodium administration normalized serum calcium and related biomarkers.
- Key markers including serum calcium, urine N-telopeptide, urine calcium/creatinine ratio, and intact parathyroid hormone returned to normal levels.
Implications:
- Oral clodronate may be a viable and effective treatment for neonatal hypercalcemia associated with subcutaneous fat necrosis.
- This case highlights the potential of bisphosphonates in managing refractory hypercalcemia in neonates.
- Further research into bisphosphonate efficacy for neonatal subcutaneous fat necrosis is warranted.
Abstract:
Hypercalcemia is occasionally found in newborns with subcutaneous fat necrosis and carries potential life-threatening risk. Bisphosphonates have been recently introduced in the treatment of subcutaneous fat necrosis in newborns. We report a case of extensive subcutaneous fat necrosis in a female infant complicated with intractable hypercalcemia. Standard treatment for hypercalcemia was given, including saline hydration, a low calcium diet, furosemide, and glucocorticoid, but without response. Serum 1,25-dihydroxyvitamin D level was elevated at 126 pg/mL, 25-hydroxyvitamin D level was normal, and intact parathyroid hormone was suppressed at < 1 pg/mL. Oral clodronate disodium, a second-generation bisphosphonate, was administered, and resulted in the normalization of serum calcium, urine N-telopeptide, urine calcium/creatinine ratio, and serum intact parathyroid hormone level. This case suggests that oral clodronate may be an effective treatment for subcutaneous fat necrosis with hypercalcemia in newborns.
Related Concept Videos
Synthesis and Functions of Calcitonin
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Osteoclasts in Bone Remodeling
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Skeleton and Calcium Homeostasis